Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 7
2005 19
2006 7
2007 15
2008 14
2009 26
2010 32
2011 23
2012 38
2013 51
2014 73
2015 64
2016 64
2017 49
2018 68
2019 64
2020 67
2021 55
2022 47
2023 34
2024 61
2025 60
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

843 results

Results by year

Filters applied: . Clear all
Page 1
Pasireotide (Signifor LAR): Therapeutic area: Acromegaly, adults: Reimbursement Review.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Oct. Report No.: SR0859-Clinical_Review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Oct. Report No.: SR0859-Clinical_Review. PMID: 41474857 Free Books & Documents. Review. No abstract available.
Pasireotide.
[No authors listed] [No authors listed] 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 31145573 Free Books & Documents. Review.
The excretion of pasireotide into breastmilk has not been studied. However, because it has a high molecular weight of 1047 daltons it is likely to be poorly excreted into breastmilk and it is a peptide that is likely digested in the infant's gastrointestinal tract. ...Howe …
The excretion of pasireotide into breastmilk has not been studied. However, because it has a high molecular weight of 1047 daltons it …
Pasireotide (Signifor): Treatment of Adult Patients with Cushing Disease.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. PMID: 26962592 Free Books & Documents. Review.
Pasireotide has a Health Canada indication for the treatment of adult patients with Cushing disease for whom surgery is not an option or for whom surgery has failed, as long as clinical benefit is derived. The maximum recommended dose is 0.9 mg twice daily. The manufacture …
Pasireotide has a Health Canada indication for the treatment of adult patients with Cushing disease for whom surgery is not an option …
Pasireotide in Acromegaly: A Review.
McKeage K. McKeage K. Drugs. 2015 Jun;75(9):1039-48. doi: 10.1007/s40265-015-0413-y. Drugs. 2015. PMID: 26017304 Review.
Pasireotide (Signifor( ), Signifor( ) LAR) is a somatostatin analogue recently approved for the treatment of acromegaly. ...The tolerability profile of intramuscular pasireotide is generally similar to that of first-generation agents, except for a high …
Pasireotide (Signifor( ), Signifor( ) LAR) is a somatostatin analogue recently approved for the treatment of acromegaly …
Meningioma.
Fathi AR, Roelcke U. Fathi AR, et al. Curr Neurol Neurosci Rep. 2013 Apr;13(4):337. doi: 10.1007/s11910-013-0337-4. Curr Neurol Neurosci Rep. 2013. PMID: 23463172 Review.
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T, Lee L, Jensen RT. Ito T, et al. Expert Opin Pharmacother. 2016 Nov;17(16):2191-2205. doi: 10.1080/14656566.2016.1236916. Epub 2016 Sep 23. Expert Opin Pharmacother. 2016. PMID: 27635672 Free PMC article. Review.
These include new medical-therapies [serotonin-synthesis inhibitors(telotristat), Pasireotide, new agents for treating ACTHomas], increased dosing with conventional therapies (octreotide-LAR, Lanreotide-Autogel), mTor inhibitors(everolimus), Tyrosine-kinase inhibitors(suni …
These include new medical-therapies [serotonin-synthesis inhibitors(telotristat), Pasireotide, new agents for treating ACTHomas], inc …
Pasireotide for the treatment of acromegaly.
Wildemberg LE, Gadelha MR. Wildemberg LE, et al. Expert Opin Pharmacother. 2016;17(4):579-88. doi: 10.1517/14656566.2016.1146688. Epub 2016 Feb 17. Expert Opin Pharmacother. 2016. PMID: 26808354 Review.
In this scenario, a next-generation SA, pasireotide, has recently been approved for the treatment of acromegaly. AREAS COVERED: 1) pasireotide's pharmacokinetics and pharmacodynamics; 2) pasireotide's anti-secretory and anti-proliferative effects, from precli …
In this scenario, a next-generation SA, pasireotide, has recently been approved for the treatment of acromegaly. AREAS COVERED: 1) …
Pasireotide.
Feelders RA, Yasothan U, Kirkpatrick P. Feelders RA, et al. Nat Rev Drug Discov. 2012 Aug;11(8):597-8. doi: 10.1038/nrd3788. Nat Rev Drug Discov. 2012. PMID: 22850776 No abstract available.
Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D, Fleseriu M. Cuevas-Ramos D, et al. Drug Des Devel Ther. 2016 Jan 11;10:227-39. doi: 10.2147/DDDT.S77999. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26811671 Free PMC article. Review.
Here, emphasis is placed on new medical therapies to control acromegaly. There is a focus on pasireotide long-acting release (LAR) (Signifor LAR ), which was approved in 2014 by the US Food and Drug Administration and the European Medicine Agency for the treatment o …
Here, emphasis is placed on new medical therapies to control acromegaly. There is a focus on pasireotide long-acting release (LAR) ( …
Pituitary acting drugs: cabergoline and pasireotide.
Gadelha MR, Wildemberg LE, Shimon I. Gadelha MR, et al. Pituitary. 2022 Oct;25(5):722-725. doi: 10.1007/s11102-022-01238-8. Epub 2022 Jun 7. Pituitary. 2022. PMID: 35670988 Review.
Pituitary-directed agents include cabergoline and pasireotide. Both drugs present similar potential for biochemical control and pasireotide has additionally been proved to reduce tumor volume. Moreover, pasireotide was evaluated in high quality studies. In re …
Pituitary-directed agents include cabergoline and pasireotide. Both drugs present similar potential for biochemical control and pa …
843 results